The Top 5 Biosimilar Articles for the Week of January 17

Here are the top 5 biosimilar articles for the week of January 17, 2022.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of January 17, 2022.

Number 5: The International Generic and Biosimilar Medicines Association has appointed a veteran member, Vivian Frittelli, MBA, ACIS, to take over as chair.

Number 4: Insulin costs increased dramatically in recent years, and study authors noted that high costs resulted in nonadherence or insulin rationing for many patients, leading to diabetic complications and even death.

Number 3: In a recent paper, Sarfaraz K. Niazi, PhD summarized some of his central ideas on the relevance of FDA biosimilar testing standards.

Number 2: Ford Motor saved $5 million by switching patients to 5 biosimilars, and other manufacturers and employers in Michigan achieved good results with switching programs, the Economic Alliance of Michigan reported.

Number 1: Amgen Chairman and CEO Robert Bradway touted the potential of 11 biosimilars driving revenues for the company by 2030.

To read all of these articles and more, visit centerforbiosimilars.com.